Growth Metrics

Fennec Pharmaceuticals (FENC) Gross Margin (2023 - 2025)

Fennec Pharmaceuticals posted quarterly Gross Margin of 55.68% for Q4 2025, up 545.0% year-on-year from 8.63% in Q4 2024, and down 4.32% on a QoQ basis from 58.19% in Q3 2025.

Fennec Pharmaceuticals (FENC) has 3 years of Gross Margin data on file, last reported at 55.68% in Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 545.0% year-over-year to 55.68%; the trailing twelve-month figure through Dec 2025 stood at 71.65% (down 621.0% YoY), and the FY2025 full-year result was 58.3%, down 294.0% from the prior year.
  • Gross Margin for Q4 2025 stood at 55.68%, down from 58.19% in the prior quarter.
  • Across five years, Gross Margin topped out at 97.83% in Q1 2024 and bottomed at 35.67% in Q2 2024.
  • The 3-year median for Gross Margin is 91.47% (2023), against an average of 78.47%.
  • The widest annual swing landed in 2024, when Gross Margin tumbled 5988 bps; it then soared 5432 bps in 2025.
  • A 3-year view of Gross Margin shows it stood at 92.96% in 2023, then sank by 46 bps to 50.23% in 2024, then increased by 11 bps to 55.68% in 2025.
  • The last three Gross Margin figures came in at 55.68% (Q4 2025), 58.19% (Q3 2025), and 89.98% (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 86.85%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 82.22%
10 Fennec Pharmaceuticals 281.48 Mn 244.70 Mn 7.67 Mn 55.68%

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 55.68%
Sep 30, 2025 58.19%
Jun 30, 2025 89.98%
Mar 31, 2025 95.74%
Dec 31, 2024 50.23%
Sep 30, 2024 80.54%
Jun 30, 2024 35.67%
Mar 31, 2024 97.83%
Dec 31, 2023 92.96%
Sep 30, 2023 94.92%
Jun 30, 2023 95.55%
Mar 31, 2023 94.34%